Wang A, Tang H, Zhang N, et al
As a once-weekly injection in 0.5 mg, 1 mg, and 2 mg doses to reduce the risk of sustained eGFR decline , end-stage renal disease and cardiovascular death in adults with type 2 diabetes and CKD under the Ozempic label
10.1016/j.bpobgyn.2018.01.011 20
First, we selected candidate residues for the potential glutathione activator site and the glutathione-scaffold site
This might involve: Increasing metformin dosage if not already at maximum tolerated dose Adding or optimising sulfonylureas such as gliclazide, though these carry hypoglycaemia risk Introducing DPP-4 inhibitors like sitagliptin or linagliptin, which are generally well-tolerated Adding pioglitazone in carefully selected patients, considering both potential benefits and significant risks (fluid retention, weight gain, heart failure risk, fracture risk, and possible bladder cancer risk) Insulin therapy may be necessary if other options are insufficient to achieve target HbA1c levels
utilizing European datasets and Chang et al
